Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
2.540
+0.040 (1.60%)
At close: Apr 1, 2025, 4:00 PM
2.555
+0.015 (0.59%)
After-hours: Apr 1, 2025, 4:02 PM EDT

Company Description

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.

It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease.

It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products.

The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Regina Graul

Contact Details

Address:
245 First Street, Riverview II, 18th Floor
Cambridge, Massachusetts 02142
United States
Phone 857 327 8778
Website cyclerion.com

Stock Details

Ticker Symbol CYCN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001755237
CUSIP Number 23255M105
ISIN Number US23255M2044
Employer ID 83-1895370
SIC Code 2834

Key Executives

Name Position
Dr. Regina Graul Ph.D. Chief Executive Officer, President and Director
Rhonda M. Chicko CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Mar 28, 2025 SCHEDULE 13D/A Filing
Mar 25, 2025 8-K Current Report
Mar 4, 2025 10-K Annual Report
Feb 12, 2025 EFFECT Notice of Effectiveness
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 UPLOAD Filing
Feb 4, 2025 S-3 Registration statement under Securities Act of 1933
Dec 17, 2024 8-K Current Report